CytoSorbents Corporation has filed an administrative appeal with the U.S. Food and Drug Administration (FDA) for a supervisory review of the De Novo Denial Letter issued for its DrugSorb™-ATR device. This device is aimed at minimizing bleeding severity in patients undergoing coronary artery bypass grafting surgery shortly after ceasing the use of the blood thinner Brilinta®. Despite receiving a Breakthrough Device Designation, the FDA has identified certain deficiencies that need to be addressed before commercialization in the U.S. The company's appeal seeks to resolve these issues through engagement with senior FDA leadership. Meanwhile, the DrugSorb-ATR application is under advanced review by Health Canada, although the process is delayed due to a backlog. CytoSorbents remains optimistic about receiving a final regulatory decision in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.